LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Strona główna・Stock List・Gilead Sciences Inc.

Gilead Sciences Inc.

Closed

SectorHealthcare

129.61 0.07

Buy Sell

Overview

Share price change

24h

Current

Min

129.13

Max

130.97

Key metrics
By Trading Economics
Income	-162M 2B
Sales	-965M 7B
P/E Sector Avg	18.191 51.415
EPS	2.03
Dividend yield	2.43
Profit margin	29.037
Employees	17,000
EBITDA	18M 2.4B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+23.34% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.43% 2.34%
Next Earnings	6 sie 2026
Next Dividend date	29 cze 2026
Next Ex Dividend date	15 cze 2026

Market Stats
By TradingEconomics
Market Cap	1.1B 166B
Previous open	129.54
Previous close	129.61

News Sentiment

By Acuity

28%

72%

48 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

97.33 / 103.17 Support & Resistance

Gilead Sciences Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 maj 2026, 20:49 UTC

Earnings

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 kwi 2026, 14:24 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 kwi 2026, 12:53 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

8 maj 2026, 08:10 UTC

Earnings

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 maj 2026, 08:08 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 maj 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 maj 2026, 21:09 UTC

Earnings

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 maj 2026, 20:51 UTC

Earnings

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 maj 2026, 20:06 UTC

Earnings

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 maj 2026, 20:05 UTC

Earnings

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 maj 2026, 20:05 UTC

Earnings

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 maj 2026, 20:02 UTC

Earnings

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 maj 2026, 20:01 UTC

Earnings

Gilead Sciences 1Q Rev $6.96B >GILD

7 maj 2026, 20:01 UTC

Earnings

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 maj 2026, 20:01 UTC

Earnings

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 maj 2026, 20:01 UTC

Earnings

Gilead Sciences 1Q EPS $1.61 >GILD

28 kwi 2026, 12:45 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 kwi 2026, 12:32 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 kwi 2026, 12:30 UTC

Acquisitions, Mergers, Takeovers

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 kwi 2026, 14:36 UTC

Acquisitions, Mergers, Takeovers

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 kwi 2026, 14:35 UTC

Acquisitions, Mergers, Takeovers

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 kwi 2026, 14:34 UTC

Acquisitions, Mergers, Takeovers

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 kwi 2026, 14:28 UTC

Acquisitions, Mergers, Takeovers

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 kwi 2026, 14:23 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 kwi 2026, 13:55 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 kwi 2026, 13:14 UTC

Acquisitions, Mergers, Takeovers

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 kwi 2026, 12:30 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 kwi 2026, 12:30 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 kwi 2026, 12:30 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

7 kwi 2026, 12:30 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Tubulis Deal Includes $3.15B Upfront Cash Consideration on Cash-Free, Debt-Free Basis >GILD

Peer Comparison

Price change

Gilead Sciences Inc. Forecast

Price Target

By TipRanks

23.34% upside

12 Months Forecast

Average 159.83 USD 23.34%

High 180 USD

Low 122 USD

Based on 22 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Gilead Sciences Inc. - Dist in the past 3 months.

Technical Score

By Trading Central

97.33 / 103.17Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Sentiment

By Acuity

48 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.